|
|
Article: Akorn, Inc. and Strides Arcolab Limited Agree to Expand the Akorn-Strides, LLC Joint Venture Product Pipeline to Twenty-Nine ANDA's.
- Article from:
- Business Wire
- Article date:
- December 6, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BUFFALO GROVE, Ill. -- Akorn, Inc. (AMEX: AKN) and Strides Arcolab Limited (NSE: STAR, BSE: 532531) today announced that both Companies have agreed to fund, develop, and commercialize an additional 10 ANDA injectable drug products for the Akorn-Strides, LLC Joint Venture. Akorn and Strides created and funded the Joint Venture in 2005 and since that time have developed and submitted 15 ANDA's. Prior to year end, the Joint Venture expects to submit an additional 2 ANDA's for a total of 17 ANDA's filed in 2006. The Joint Venture is developing liquid, lyophilized and dry powder fill generic injectable products targeting several therapeutic markets with a major focus on ...
Related newspaper, magazine, and journal articles:
|
|
Article: Akorn Issues Important Business Updates:-- Purchase of ...
Business Wire;
April 1, 2009 ;
700+ words
...LAKE FOREST, Ill. -- Akorn, Inc. (NASDAQ: AKRX) today ... rights as the lender under Akorn's Credit Agreement with GE ... the FDA. Additionally, our joint venture with Strides Arcolab will be ... Injection in Q2'09. About Akorn, Inc. Akorn, Inc. manufactures ...
|
|